Below is a list of links related to vaccines, and updated regularly:
Below is a list of articles related to vaccines, and updated regularly:
Rubin E, et al. "Audio Interview: Waning Immunity against Covid-19." May 26, 2022 N Engl J Med 2022; 386:e64 https://doi.org/10.1056/NEJMe2206981.
Accorsi E, et al. "Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron." NEJM May 25, 2022 https://doi.org/10.1056/NEJMc2203165.
Goldberg Y, et al. "Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2." NEJM May 25, 2022 https://doi.org/10.1056/NEJMoa2118946.
Brown P, et al. "Omicron BA.1/1.1 SARS-CoV-2 Infection among Vaccinated Canadian Adults." NEJM May 18, 2022 https://doi.org/10.1056/NEJMc2202879.
Evans J, et al. "Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants." NEJM May 18, 2022 https://doi.org/10.1056/NEJMc2205019.
Anderson E, et al. "Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age." NEJM May 11, 2022 https://doi.org/10.1056/NEJMoa2203315.
Rubin E, et al. "Audio Interview: Do We Need New Covid-19 Vaccines?" May 5, 2022 N Engl J Med 2022; 386:e52 https://doi.org/10.1056/NEJMe2205974.
Ten Doesschate T, et al. "Efficacy of Bacillus Calmette-Guerin vaccination against respiratory tract infections in the elderly during the Covid-19 pandemic." Clin Infect Dis. 2022 Mar 5. https://doi.org/10.1093/cid/ciac182.
Gray G, et al. "Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa." NEJM May 4, 2022 https://doi.org/10.1056/NEJMc2202061.
Nohynek H, et al. "Does the World Still Need New Covid-19 Vaccines?" NEJM May 4, 2022 https://doi.org/10.1056/NEJMe2204695.
Hager K, et al. "Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine." NEJM May 4, 2022 https://doi.org/10.1056/NEJMoa2201300.
Dai L, et al. "Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults." NEJM May 4, 2022 https://doi.org/10.1056/NEJMoa2202261.
Syed AA, et al. "Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review." Immunol Med. 2022 May 1:1-13. https://doi.org/10.1080/25785826.2022.2068331.
Noori M, et al. "Recent developments in SARS-CoV-2 vaccines: A systematic review of the current studies." Rev Med Virol. 2022 May 1:e2359. https://doi.org/10.1002/rmv.2359.
Husby A, et al. "SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents." JAMA Cardiol. 2022 Apr 20. https://doi.org/10.1001/jamacardio.2022.0583.
Shi Y, et al. "Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Adolescents, Children, and Infants: A Systematic Review and Meta-Analysis." Front Public Health. 2022 Apr 14;10:829176. https://doi.org/10.3389/fpubh.2022.829176. eCollection 2022.
Magen O, et al. "Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting." NEJM April 13, 2022 https://doi.org/10.1056/NEJMoa2201688.
Offit P, et al. "Covid-19 Boosters — Where from Here?" NEJM April 13, 2022 https://doi.org/10.1056/NEJMe2203329.
Casanegra AI, et al. "Risk of venous thromboembolism after COVID-19 vaccination." J Thromb Haemost. 2022 Apr 10. https://doi.org/10.1111/jth.15725.
Yoon S, et al. "Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers." NEJM April 6, 2022 https://doi.org/10.1056/NEJMc2201821.
Rubin E, et al. "Audio Interview: Do We Need a Fourth Dose of Covid Vaccine?" April 7, 2022 N Engl J Med 2022; 386:e45 https://doi.org/10.1056/NEJMe2204616.
Ramaiah V, et al. "Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India." Lancet. 2022 Apr 2;399(10332):1313-1321. https://doi.org/10.1016/S0140-6736(22)00151-9. (Original study)
Wang YP, et al. "SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systemic review and meta-analysis." J Chin Med Assoc. 2022 Apr 1;85(4):421-430. https://doi.org/10.1097/JCMA.0000000000000682.
Rubin E, et al. "Audio Interview: Effectiveness of Covid-19 Vaccination in Children." March 31, 2022 N Engl J Med 2022; 386:e39 https://doi.org/10.1056/NEJMe2204268.
Klein N, et al. "Added Benefit of Covid-19 Vaccination after Previous Infection." March 31, 2022 N Engl J Med 2022; 386:1278-1279 https://doi.org/10.1056/NEJMe2201380.
Bansal V, et al. "Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: A systematic review, meta-analysis and meta-regression." Aliment Pharmacol Ther. 2022 Mar 30. https://doi.org/10.1111/apt.16913.
Dahlqwist E, et al. "Association of SARS-CoV-2 Vaccination During Pregnancy With Pregnancy Outcomes." JAMA. 2022 Mar 24. https://doi.org/10.1001/jama.2022.3271.
Alton GD, et al. "Association of COVID-19 Vaccination in Pregnancy With Adverse Peripartum Outcomes." JAMA. 2022 Mar 24. https://doi.org/10.1001/jama.2022.4255.
Moreira E, et al. "Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine." NEJM March 23, 2022 https://doi.org/10.1056/NEJMoa2200674.
Rubin E, et al. "Audio Interview: Can We Make More Effective Covid-19 Vaccines?" March 17, 2022 N Engl J Med 2022; 386:e36 https://doi.org/10.1056/NEJMe2203667.
Roel E, et al. "Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis." BMJ. 2022 Mar 16;376:e068373. https://doi.org/10.1136/bmj-2021-068373.
Rohban T, et al. "BNT162b2 Vaccine Booster and Covid-19 Mortality." March 10, 2022 N Engl J Med 2022; 386:1000-1001 https://doi.org/10.1056/NEJMc2120044.
Liu Q, et al. "Effectiveness and Safety of SARS-CoV-2 Vaccines among Children and Adolescents: A Systematic Review and Meta-Analysis." Vaccines (Basel). 2022 Mar 10;10(3). https://doi.org/10.3390/vaccines10030421.
Sablerolles R, et al. "Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming." March 10, 2022 N Engl J Med 2022; 386:951-963 https://doi.org/10.1056/NEJMoa2116747.
Rubin E, et al. "Audio Interview: Making Covid-19 Vaccines Available around the World." March 10, 2022 N Engl J Med 2022; 386:e31 https://doi.org/10.1056/NEJMe2203379.
Bachmann M, et al. "The Future of SARS-CoV-2 Vaccination." March 3, 2022 N Engl J Med 2022; 386:899-900 https://doi.org/10.1056/NEJMc2119437.
Jones LF, et al. "The Effectiveness of Interventions for Increasing COVID-19 Vaccine Uptake: A Systematic Review." Vaccines (Basel). 2022 Mar 3;10(3). https://doi.org/10.3390/vaccines10030386.
Taytard J, et al. "More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age." NEJM March 2, 2022 https://doi.org/10.1056/NEJMc2201556.
Hunter D, et al. "Addressing Vaccine Inequity — Covid-19 Vaccines as a Global Public Good." NEJM February 23, 2022 https://doi.org/10.1056/NEJMe2202547.
Alunno A, et al. "EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update." Ann Rheum Dis. 2022 Feb 23. https://doi.org/10.1136/annrheumdis-2021-222006.
Hamdy NA, et al. "Efficacy and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis." Vaccines (Basel). 2022 Feb 23;10(3). https://doi.org/10.3390/vaccines10030350.
Madhi S, et al. "Population Immunity and Covid-19 Severity with Omicron Variant in South Africa." NEJM February 23, 2022 https://doi.org/10.1056/NEJMoa2119658.
Abu-Raddad LJ, et al. "Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression." Lancet. 2022 Feb 21. https://doi.org/10.1016/S0140-6736(22)00152-0.
Hall V, et al. "Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection." NEJM February 16, 2022 https://doi.org/10.1056/NEJMoa2118691.
Hammerman A, et al. "Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19." NEJM February 16, 2022 https://doi.org/10.1056/NEJMoa2119497.
Altarawneh H, et al. "Protection against the Omicron Variant from Previous SARS-CoV-2 Infection." NEJM February 9, 2022 https://doi.org/10.1056/NEJMc2200133.
Mayr F, et al. "Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans." NEJM February 9, 2022 https://doi.org/10.1056/NEJMc2200415.
Sadoff J, et al. "Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S." NEJM February 9, 2022 https://doi.org/10.1056/NEJMoa2117608.
Collie S, et al. "Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa." February 3, 2022 N Engl J Med 2022; 386:494-496 https://doi.org/10.1056/NEJMc2119270.
Harville T, et al. "Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination." February 2, 2022 https://doi.org/10.1056/NEJMc2119443.
Wang Y, et al. "Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: A self-controlled case series and nested case-control study." Lancet Reg Health West Pac. 2022 Apr;21:100393. https://doi.org/10.1016/j.lanwpc.2022.100393. Epub 2022 Feb 2.
Budi DS, et al. "mRNA Covid-19 vaccines in pregnancy: A systematic review." PLoS One. 2022 Feb 2;17(2):e0261350. https://doi.org/10.1371/journal.pone.0261350. eCollection 2022.
Bouzas MB, et al. "Immunogenicity induced by the use of alternative vaccine platforms to deal with vaccine shortages in a low- to middle-income country: Results of two randomized clinical trials." Lancet Reg Health Am. 2022 May;9:100196. https://doi.org/10.1016/j.lana.2022.100196. Epub 2022 Feb 2.
McConeghy K, et al. "Evaluating the Findings of the IMPACT-C Randomized Clinical Trial to Improve COVID-19 Vaccine Coverage in Skilled Nursing Facilities." JAMA Intern Med. 2022 Jan 31. https://doi.org/10.1001/jamainternmed.2021.8067.
Guo X, et al. "Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial." Nat Med. 2022 Feb;28(2):401-409. https://doi.org/10.1038/s41591-021-01677-z. Epub 2022 Jan 27.
Andrews N, et al. "Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines." January 27, 2022 N Engl J Med 2022; 386:340-350 https://doi.org/10.1056/NEJMoa2115481.
Chemaitelly H, et al. "Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar." NEJM January 26, 2022 https://doi.org/10.1056/NEJMc2119432.
Atmar R, et al. "Homologous and Heterologous Covid-19 Booster Vaccinations." NEJM January 26, 2022 https://doi.org/10.1056/NEJMoa2116414.
Zhao X, et al. "Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant." NEJM January 26, 2022 https://doi.org/10.1056/NEJMc2119426.
Veroniki AA, et al. "Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials." PLoS One. 2022 Jan 21;17(1):e0260733. https://doi.org/10.1371/journal.pone.0260733. eCollection 2022.
Clemens R, et al. "Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study." Lancet. 2022 Jan 21. https://doi.org/10.1016/S0140-6736(22)00094-0.
Chemaitelly H, et al. "Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar." NEJM January 19, 2022 https://doi.org/10.1056/NEJMc2117933.
Tran TM, et al. "Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine." Biomed Pharmacother. 2022 Jan 19;147:112650. https://doi.org/10.1016/j.biopha.2022.112650.
Sablerolles R, et al. "Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming." NEJM January 19, 2022 https://doi.org/10.1056/NEJMoa2116747.
Tobudic S, et al. "Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial." Ann Rheum Dis. 2022 Jan 13. https://doi.org/10.1136/annrheumdis-2021-221558.
Lin D, et al. "Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina." NEJM January 12, 2022 https://doi.org/10.1056/NEJMoa2117128.
Olson S, et al. "Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents." NEJM January 12, 2022 https://doi.org/10.1056/NEJMoa2117995.
Veiga-Gutierrez R, et al. "Effects of Loigolactobacillus coryniformis K8 CECT 5711 on the Immune Response of Elderly Subjects to COVID-19 Vaccination: A Randomized Controlled Trial." Nutrients. 2022 Jan 5;14(1). https://doi.org/10.3390/nu14010228.
Eyre D, et al. "Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants." NEJM January 5, 2022 https://doi.org/10.1056/NEJMoa2116597.
Collie S, et al. "Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa." NEJM December 29, 2021 https://doi.org/10.1056/NEJMc2119270.
Lacy J, et al. "VITT and Second Doses of Covid-19 Vaccine." NEJM December 22, 2021 https://doi.org/10.1056/NEJMc2118507.
Foxworth R, et al. "Covid-19 Vaccination in American Indians and Alaska Natives — Lessons from Effective Community Responses." NEJM December 18, 2021 https://doi.org/10.1056/NEJMp2113296.
Rubin E, et al. "Audio Interview: How Much Protection Does Prior SARS-CoV-2 Infection Provide?" December 16, 2021 N Engl J Med 2021; 385:e100 https://doi.org/10.1056/NEJMe2119539.
Lilleri D, et al. "SARS-CoV-2 Infection in Vaccinated Health Care Workers." NEJM December 15, 2021 https://doi.org/10.1056/NEJMc2117119.
Chemaitelly H, et al. "Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant." NEJM December 15, 2021 https://doi.org/10.1056/NEJMc2110300.
Chemaitelly H, et al. "Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar." December 9, 2021 N Engl J Med 2021; 385:e83 https://doi.org/10.1056/NEJMoa2114114.
Rubin E, et al. "Audio Interview: Waning Immunity against SARS-CoV-2." December 9, 2021 N Engl J Med 2021; 385:e99 https://doi.org/10.1056/NEJMe2119211.
Bar-On Y, et al. "Protection against Covid-19 by BNT162b2 Booster across Age Groups." NEJM December 8, 2021 https://doi.org/10.1056/NEJMoa2115926.
McGarry B, et al. "Nursing Home Staff Vaccination and Covid-19 Outcomes." NEJM December 8, 2021 https://doi.org/10.1056/NEJMc2115674.
Alunno A, et al. "Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations." Ann Rheum Dis. 2021 Dec 7. https://doi.org/10.1136/annrheumdis-2021-221575.
Neoh ZCF, et al. "Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis." Blood Adv. 2022 Apr 12;6(7):2014-2034. https://doi.org/10.1182/bloodadvances.2021006333.
Witberg G, et al. "Myocarditis after Covid-19 Vaccination in a Large Health Care Organization." December 2, 2021 N Engl J Med 2021; 385:2132-2139 https://doi.org/10.1056/NEJMoa2110737.
Caforio A, et al. "Receipt of mRNA Vaccine against Covid-19 and Myocarditis." December 2, 2021 N Engl J Med 2021; 385:2189-2190 https://doi.org/10.1056/NEJMe2116493.
Cornelius V, et al. "Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial." Lancet. 2021 Dec 2. https://doi.org/10.1016/S0140-6736(21)02717-3.
Fauver J, et al. "Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons." NEJM December 1, 2021 https://doi.org/10.1056/NEJMc2102507.
Rosenberg E, et al. "Covid-19 Vaccine Effectiveness in New York State." NEJM December 1, 2021 https://doi.org/10.1056/NEJMoa2116063.
Dickerman B, et al. "Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans." NEJM December 1, 2021 https://doi.org/10.1056/NEJMoa2115463.
Kohler S, et al. "Vaccine-Induced Thrombocytopenia with Severe Headache." November 25, 2021 N Engl J Med 2021; 385:2103-2105 https://doi.org/10.1056/NEJMc2112974.
Murphy W, et al. "A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination." NEJM November 24, 2021 https://doi.org/10.1056/NEJMcibr2113694.
Ongarj J, et al. "Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population." Vaccines (Basel). 2021 Nov 23;9(12). https://doi.org/10.3390/vaccines9121375.
Cosgrove C, et al. "Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial." Lancet Respir Med. 2021 Nov 17. https://doi.org/10.1016/S2213-2600(21)00409-4.
Monto A, et al. "The Future of SARS-CoV-2 Vaccination — Lessons from Influenza." November 11, 2021 N Engl J Med 2021; 385:1825-1827 https://doi.org/10.1056/NEJMp2113403.
Torgovnick J, et al. "Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant." NEJM November 10, 2021 https://doi.org/10.1056/NEJMc2113090.
Baden L, et al. "Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase." November 4, 2021 N Engl J Med 2021; 385:1774-1785 https://doi.org/10.1056/NEJMoa2113017.
Santin A, et al. "VITT after ChAdOx1 nCoV-19 Vaccination." NEJM November 3, 2021 https://doi.org/10.1056/NEJMc2111026.
Baden L, et al. "Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge." NEJM November 3, 2021 https://doi.org/10.1056/NEJMc2115597.
Tartour E, et al. "Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review." Clin Microbiol Infect. 2021 Oct 28. https://doi.org/10.1016/j.cmi.2021.09.036.
Noorchashm H, et al. "Equivalency of Protection From Natural Immunity in COVID-19 Recovered Versus Fully Vaccinated Persons: A Systematic Review and Pooled Analysis." Cureus. 2021 Oct 28;13(10):e19102. https://doi.org/10.7759/cureus.19102. eCollection 2021 Oct.
Rubin E, et al. "Audio Interview: A New Look at Covid-19 Vaccine Boosters." October 21, 2021 N Engl J Med 2021; 385:e72 https://doi.org/10.1056/NEJMe2116820.
Magnus M, et al. "Covid-19 Vaccination during Pregnancy and First-Trimester Miscarriage." NEJM October 20, 2021 https://doi.org/10.1056/NEJMc2114466.
Kulper-Schiek W, et al. "Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021." Euro Surveill. 2021 Oct;26(41). 14 Oct 2021 https://doi.org/10.2807/1560-7917.ES.2021.26.41.2100920.
Rubin E, et al. "Audio Interview: Are Covid-19 Vaccine Boosters Necessary?" October 7, 2021 N Engl J Med 2021; 385:e63 https://doi.org/10.1056/NEJMe2115835.
Sanders J, et al. "Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines." November 4, 2021 N Engl J Med 2021; 385:1817-1821 https://doi.org/10.1056/NEJMc2113575.
Tian YC, et al. "Immunogenicity Rates After SARS-CoV-2 Vaccination in People With End-stage Kidney Disease: A Systematic Review and Meta-analysis." JAMA Netw Open. 2021 Oct 1;4(10):e2131749. https://doi.org/10.1001/jamanetworkopen.2021.31749.
Shen Q, et al. "Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review." Vaccines (Basel). 2021 Sep 29;9(10). https://doi.org/10.3390/vaccines9101102.
Sikron FH, et al. "Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine, historical cohort study." Clin Microbiol Infect. 2021 Sep 27. https://doi.org/10.1016/j.cmi.2021.09.018.
Sahly H, et al. "Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase." NEJM September 22, 2021 https://doi.org/10.1056/NEJMoa2113017.
Yeung WWY, et al. "Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong." Ann Rheum Dis. 2021 Oct 22. https://doi.org/10.1136/annrheumdis-2021-221571.
Toscani I, et al. "COVID-19 Vaccines in Cancer Patients. Seropositivity and Safety." Systematic Review and Meta-Analysis. Vaccines (Basel). 2021 Sep 20;9(9). https://doi.org/10.3390/vaccines9091048.
As part of K2P COVID-19 Series, K2P center is pleased to launch the latest product: “A Closer Look at COVID-19 Vaccines: The Known, the Unknown, and the Uncertain”. (Arabic Version) , (English Version) , (Full Product Version)
This is the second product on the COVID-19 Vaccine developed by K2P. To know more about the first product, you can check at: Countdown to a COVID-19 Vaccine: Spotlight on Lebanon
Images